Prasugrel Besylate is a thienopyridine derivative and a potent platelet aggregation inhibitor used to prevent cardiovascular thrombotic events in patients with acute coronary syndrome or those undergoing… Read more
Prasugrel Besylate is a thienopyridine derivative and a potent platelet aggregation inhibitor used to prevent cardiovascular thrombotic events in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention. By irreversibly binding to the P2Y12 ADP receptor, it inhibits platelet activation and reduces the risk of stent thrombosis. This category includes high-quality reference standards for Prasugrel Besylate API, alongside its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these materials for rigorous impurity profiling, analytical method development, and the precise quantification required for quality control validation. These standards are essential for ensuring regulatory compliance and maintaining the consistent efficacy and safety of pharmaceutical products during stability testing and routine release analysis.